Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: A pooled analysis of patient-level data

Philippe Gabriel Steg, Deepak L. Bhatt, Christian W. Hamm, Gregg W. Stone, C. Michael Gibson, Kenneth W. Mahaffey, Sergio Leonardi, Tiepu Liu, Simona Skerjanec, Jonathan R. Day, Robert S. Iwaoka, Thomas D. Stuckey, Harinder S. Gogia, Luis Gruberg, William J. French, Harvey D. White, Robert A. Harrington

Research output: Contribution to journalArticlepeer-review

Abstract

Background Cangrelor is a potent, rapid-acting, reversible intravenous platelet inhibitor that was tested for percutaneous coronary intervention (PCI) in three large, double-blind, randomised trials. We did a pooled analysis of data from three trials that assessed the eff ectiveness of cangrelor against either clopidogrel or placebo in PCI. Methods This prespecifi ed, pooled analysis of patient-level data from three trials (CHAMPION-PCI, CHAMPIONPLATFORM, and CHAMPION-PHOENIX) compared cangrelor with control (clopidogrel or placebo) for prevention of thrombotic complications during and after PCI. Trial participants were patients undergoing PCI for ST-elevation myocardial infarction (11.6%), non-ST-elevation acute coronary syndromes (57.4%), and stable coronary artery disease (31.0%). Effi cacy was assessed in the modifi ed intention-to-treat population of 24 910 patients, with a prespecifi ed primary effi cacy composite of death, myocardial infarction, ischaemia-driven revascularisation, or stent thrombosis at 48 h. The primary safety outcome was non-coronary artery bypass graft-related GUSTO (Global Use of Strategies to Open Occluded Coronary Arteries) severe or life-threatening bleeding at 48 h. Findings Cangrelor reduced the odds of the primary outcome by 19% (3.8% for cangrelor vs 4.7% for control; odds ratio [OR] 0.81, 95% CI 0.71-0.91, p=0.0007), and stent thrombosis by 41% (0.5% vs 0.8%, OR 0.59, 95% CI 0.43-0.80, p=0.0008). Cangrelor reduced the odds of the secondary triple composite (all-cause death, myocardial infarction, or ischaemia-driven revascularisation at 48 h) by 19% (3.6% vs 4.4%, OR 0.81, 95% CI 0.71-0.92, p=0.0014). Effi cacy outcomes were consistent across the trials and main patient subsets. These benefi ts were maintained at 30 days. There was no diff erence in the primary safety outcome (0.2% in both groups), in GUSTO moderate bleeding (0.6% vs 0.4%), or in transfusion (0.7% vs 0.6%), but cangrelor increased GUSTO mild bleeding (16.8% vs 13.0%, p<0.0001). Interpretation Compared with control (clopidogrel or placebo), cangrelor reduced PCI periprocedural thrombotic complications, at the expense of increased bleeding. Funding The Medicines Company.

Original languageEnglish
Pages (from-to)1981-1992
Number of pages12
JournalLancet
Volume382
Issue number9909
DOIs
Publication statusPublished - 2013

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: A pooled analysis of patient-level data'. Together they form a unique fingerprint.

Cite this